Two semi-synthetic indolocarbazole derivatives, ED-11O and NB- 506, have been described as potent inhibitors of topoisomerase I, an enzyme critical for cell viability and an important target for anticancer drug design. These analogues showed impressive in vitro and in vivo antitumor activities. Few topoisomerase 1 inhibitors of this class are known, and most are semi-synthetic derivatives of microbial natural products, severely limiting the structural diversity examined for biological activity. We will prepare, via total synthesis, a series of indolocarbazoles core structures, as well as structural analogues. The compounds will be evaluated for inhibition of human topoisomerase I, and this activity will be correlated with in vitro cytotoxicity against a panel of human tumor cell lines. The long range goal of this project is to identify a candidate for development as a clinically useful antitumor agent.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Small Business Innovation Research Grants (SBIR) - Phase I (R43)
Project #
1R43CA072328-01A1
Application #
2010454
Study Section
Special Emphasis Panel (ZRG3-SSS-Z (09))
Project Start
1997-07-01
Project End
1997-12-31
Budget Start
1997-07-01
Budget End
1997-12-31
Support Year
1
Fiscal Year
1997
Total Cost
Indirect Cost
Name
Medichem Research, Inc.
Department
Type
DUNS #
City
Lemont
State
IL
Country
United States
Zip Code
60439
Zembower, D E; Zhang, H; Lineswala, J P et al. (1999) Indolocarbazole poisons of human topoisomerase I: regioisomeric analogues of ED-110. Bioorg Med Chem Lett 9:145-50